Icoria Awarded $1.2 Million Liver Injury Contract from NIEHS
Icoria is currently developing multi-analyte biomarker panels to diagnose drug-induced hepatotoxicity, non-alcoholic fatty liver disease and other liver problems where present diagnostics approaches may be limited in sensitivity and accuracy. The contract will support Icoria's continued research into proprietary serum and urine biomarkers that can measure liver health and predict the severity of liver pathology.
The SBIR Phase II contract is worth up to $1,213,492 over a two-year period. This project is funded with Federal funds from the National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services. Icoria estimates that the Federal funds allocated under these contracts will entirely support its "Metabolomics and Pathway Linkage: Urine, Serum, and liver" research program.
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.